[
    {
        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "REu5cT6GSQlz7beCfElVMB5suGKEJP9+1to4+h9GOnksXBecoiSlb0R29gkuVOeTemb+2BW4ypilUjBHUaWVXuoROvoVamgXbfzjPQmjYCPs+mzQxLgTx7JI8dNwEOetuxhW0BCVUXOWCEdZamuR4WoaSxco+X9oXsF2OjgmK3o="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-23T12:51:12.336+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_1558",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RA91FULNrg0uNy9D0w981ZIIzwN35MqeTtrKP1dXpZTPE#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_1558"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB14125"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"Benazepril hydrochloride tablets are contraindicated in patients:   who are hypersensitive to benazepril or to any other ACE inhibitor  with a history of angioedema with or without previous ACE inhibitor treatment  Benazepril hydrochloride tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer benazepril hydrochloride tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor  [see  Warnings and Precautions (5.2) Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including benazepril hydrochloride tablets in patients with diabetes  [see  Drug Interactions (7.4)    Angioedema or history of hereditary or idiopathic angioedema (  4  Hypersensitivity (  4  Coadministration with aliskiren in patients with diabetes (  4\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB14125",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    }
]